Table of Contents
ISRN Cardiology
Volume 2011 (2011), Article ID 816025, 4 pages
http://dx.doi.org/10.5402/2011/816025
Research Article

Association of PPAR 𝜶 Intron 7 Polymorphism with Coronary Artery Disease: A Cross-Sectional Study

1Division of Cellular and Molecular Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram 695 011, India
2Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram 695 011, India

Received 14 February 2011; Accepted 13 March 2011

Academic Editor: E. Liberopoulos

Copyright © 2011 Sreeja Purushothaman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Bordet, T. Ouk, O. Petrault et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1341–1346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Cresci, “The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics,” Expert Opinion on Pharmacotherapy, vol. 6, no. 15, pp. 2577–2591, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Jamshidi, H. E. Montgomery, H. W. Hense et al., “Peroxisome proliferator-activated receptor α gene regulates left ventricular growth in response to exercise and hypertension,” Circulation, vol. 105, no. 8, pp. 950–955, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Flavell, Y. Jamshidi, E. Hawe et al., “Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease,” Circulation, vol. 105, no. 12, pp. 1440–1445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar
  6. I. C. Ozturk and A. A. Killeen, “An overview of genetic factors influencing plasma lipid levels and coronary artery disease risk,” Archives of Pathology and Laboratory Medicine, vol. 123, no. 12, pp. 1219–1222, 1999. View at Google Scholar · View at Scopus
  7. K. Sankaranarayanan, R. Chakraborty, and E. A. Boerwinkle, “Ionizing radiation and genetic risks VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus,” Mutation Research, vol. 436, no. 1, pp. 21–57, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Breslow, “Genetics of lipoprotein abnormalities associated with coronary heart disease susceptibility,” Annual Review of Genetics, vol. 34, pp. 233–254, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. D. M. Flavell, H. Ireland, J. W. Stephens et al., “Peroxisome proliferator-activated receptor α gene variation influences age of onset and progression of type 2 diabetes,” Diabetes, vol. 54, no. 2, pp. 582–586, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. D. M. Flavell, I. Pineda Torra, Y. Jamshidi et al., “Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects,” Diabetologia, vol. 43, no. 5, pp. 673–680, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Foucher, S. Rattier, D. M. Flavell et al., “Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes,” Pharmacogenetics, vol. 14, no. 12, pp. 823–829, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. S. F. Doney, B. Fischer, S. Lee, A. D. Morris, G. P. Leese, and C. N. A. Palmer, “Association of common variation in the PPARα gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study,” Nuclear Receptor, vol. 3, pp. 1–7, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Schonfeld, “The effects of fibrates on lipoprotein and hemostatic coronary risk factors,” Atherosclerosis, vol. 111, no. 2, pp. 161–174, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Frick, M. Syvänne, M. S. Nieminen et al., “Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol,” Circulation, vol. 96, no. 7, pp. 2137–2143, 1997. View at Google Scholar · View at Scopus
  15. M. F. Oliver, J. A. Heady, J. N. Morris, and J. Cooper, “W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the committee of principal investigators,” The Lancet, vol. 2, no. 8191, pp. 379–385, 1980. View at Google Scholar · View at Scopus